Buy more Mobic and Save more.

Feb. 17, 2005 - All of the arthritis drugs in the family that includes Vioxx appear to raise the risk of heart attacks and strokes, several members of an FDA panel suggested Wednesday.
Late in a second day of an FDA inquiry into the safety of the drugs, experts appeared to lean heavily toward the conclusion that safety concerns that drove Vioxx from the market in September apply to other similar drugs, known collectively as Cox-2 inhibitors. Several suggested that incre…

Arthritis now affects 1-in-every-6 Americans, making it one of the most widespread diseases in the United States. In total there are 46 million doctor-diagnosed cases, and experts predict that count to rise to 67 million by 2020.
In a recent study by the Centers for Disease Control, cases were expected to rise in all but two states and the D…

DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/research/0d0629/forecast_insight) has announced the addition of the “Forecast Insight: Osteoarthritis” report to their offering.
Introduction
With several recent non-approvable decisions in the osteoarthritis market since 2006, We have updated its forecast to account for the effect on the market. We have revised the marke…

CONTRACT SALES firm Ventiv Health has signed an agreement with Boehringer Ingelheim to expand its existing relationship in support of Boehringer’s primary care sales group.
Financial terms of the deal were not disclosed.
According to Ventiv, the agreement will include “a…

Question: Before Vioxx was recalled, my wife and I both took the pain reliever Mobic. She had to spend two nights in the hospital with symptoms of a heart attack. It was a false alarm, but expensive!
I too had chest discomfort, and my cardiologist did tests. They were negative — and expensive.
I decided Mobic was responsible, and we both stopped it. When the Vioxx story broke, I concluded that these problems were a class effect, but I never saw Mobic mentioned….

WASHINGTON — The first generic forms of meloxicam and venlafaxine have been approved by the Food and Drug Administration.

The former is marketed under the Mobic brand name by Boehringer Ingelheim Ltd. as a treatment for osteoarthritis; the latter, which Wyeth markets under the Effexor trade name, is indicated for the treatment of major depressive disorder.

The clearance of meloxicam was the result of a “clus…

Byline: Adam Cresswell

Most Popular
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
Not business as usual: Changing channels in consumer electr…

(meloxicam, Boehringer Ingelheim)
A nonsteroidal anti-inflammatory drug for osteoarthritis.
* Recommended Dosage: Starting at 7.5 mg daily up to 15 mg daily if necessary.
* Special Considerations: GI side-effect rates in Mobic-treated patients in a 12-week study were 17%-20%,…

THE HARTFORD’S TOP 10
DRUGS IN 2005 WORKERS’
COMPENSATION

(RANKED BY TOTAL $ COSTS)

RANK RANK RANK COST INCREASE * COST INCREASE *
DRUG NAME 2005 2004 2003 2005 VS. 2004 2004 VS. 2003

OXYCONTIN 1 1 1 13% 2%
GABAPENTIN 2 N/A N/A 25% -34%
YDROCODONE 3 4 4 -4% -2%
LIDODERM 4 8 11 11% …

Boehringer Ingelheim should stop running a DTC print ad for its COX-2 arthritis inhibitor Mobic (meloxicam) because it contained a misleading comparative claim, the FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) told the firm in a recent letter.
The ad’s bolded headline,”Att…